An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

Harish Nair; Vasundhara R Verma; Evropi Theodoratou; Lina Zgaga; Tanvir Huda; Eric A F Simões; Peter F Wright; Igor Rudan; Harry Campbell

doi:10.1186/1471-2458-11-S3-S30

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

Harish Nair, Vasundhara R Verma, Evropi Theodoratou, Lina Zgaga, Tanvir Huda, Eric A F Simões, Peter F Wright, Igor Rudan, Harry Campbell

Research output: Contribution to journal › Article › peer-review

Abstract

Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization.

Original language	English
Pages (from-to)	S30
Journal	BMC Public Health
Volume	11 Suppl 3
DOIs	https://doi.org/10.1186/1471-2458-11-S3-S30
Publication status	Published - 2011

Access to Document

10.1186/1471-2458-11-S3-S30

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children
© 2011 Nair et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 474 KB

http://www.biomedcentral.com/1471-2458/11/S3/S30

Cite this

@article{e8bc8bc662fe419ca56f6137997a0960,

title = "An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children",

abstract = "Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization.",

author = "Harish Nair and Verma, {Vasundhara R} and Evropi Theodoratou and Lina Zgaga and Tanvir Huda and Sim{\~o}es, {Eric A F} and Wright, {Peter F} and Igor Rudan and Harry Campbell",

year = "2011",

doi = "10.1186/1471-2458-11-S3-S30",

language = "English",

volume = "11 Suppl 3",

pages = "S30",

journal = "BMC Public Health",

issn = "1471-2458",

publisher = "BioMed Central",

}

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. / Nair, Harish; Verma, Vasundhara R; Theodoratou, Evropi; Zgaga, Lina; Huda, Tanvir; Simões, Eric A F; Wright, Peter F; Rudan, Igor ; Campbell, Harry.

In: BMC Public Health, Vol. 11 Suppl 3, 2011, p. S30.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

AU - Nair, Harish

AU - Verma, Vasundhara R

AU - Theodoratou, Evropi

AU - Zgaga, Lina

AU - Huda, Tanvir

AU - Simões, Eric A F

AU - Wright, Peter F

AU - Rudan, Igor

AU - Campbell, Harry

PY - 2011

Y1 - 2011

N2 - Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization.

AB - Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization.

U2 - 10.1186/1471-2458-11-S3-S30

DO - 10.1186/1471-2458-11-S3-S30

M3 - Article

C2 - 21501449

VL - 11 Suppl 3

SP - S30

JO - BMC Public Health

JF - BMC Public Health

SN - 1471-2458

ER -

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

Abstract

Access to Document

Fingerprint

Cite this